Antibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 320211 - Provider product page
- Provider
- BioLegend
- Proper citation
- BioLegend Cat#320211, RRID:AB_430886
- Product name
- Alexa Fluor® 488 anti-human FOXP3 [259D]
- Antibody type
- Monoclonal
- Antigen
- full-length FOXP3 protein
- Description
- FOXP3 is a 50-55 kD transcription factor, also known as Forkhead box protein P3, Scurfin, JM2, or IPEX. It is proposed to be a master regulatory gene and more specific marker of T regulatory cells than most cell surface markers (such as CD4 and CD25). Transduced expression of FOXP3 in CD4+/CD25- cells has been shown to induce GITR, CD103, and CTLA4 and impart a T regulatory cell phenotype. FOXP3 is mutated in X-linked autoimmunity-allergic dysregulation syndrome (XLAAD or IPEX) in humans and in "scurfy" mice. Overexpression of FOXP3 has been shown to lead to a hypoactive immune state suggesting that this transcriptional factor is a central regulator of T cell activity. In human, unlike in mouse, two isoforms of FOXP3 have been reported: one (FOXP3) corresponding to the canonical full-length sequence; the other (FOXP3 δ2) lacking exon 2. The 259D antibody recognizes human FOXP3 epitope in the region of amino acids 105-235.
- Reactivity
- Human, Simian
- Host
- Mouse
- Conjugate
- Green dye
- Isotype
- IgG
- Vial size
- 25 tests
- Storage
- The FOXP3 antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Submitted references CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells.
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression.
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.
Defense of the clone: antibody 259D effectively labels human FOXP3 in a variety of applications.
Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH
Science translational medicine 2012 May 16;4(134):134ra62
Science translational medicine 2012 May 16;4(134):134ra62
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells.
Tresoldi E, Dell'Albani I, Stabilini A, Jofra T, Valle A, Gagliani N, Bondanza A, Roncarolo MG, Battaglia M
Haematologica 2011 Sep;96(9):1357-65
Haematologica 2011 Sep;96(9):1357-65
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH
Blood 2011 Jan 20;117(3):788-97
Blood 2011 Jan 20;117(3):788-97
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jul 1;16(13):3485-94
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jul 1;16(13):3485-94
FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression.
Torgerson TR, Genin A, Chen C, Zhang M, Zhou B, Añover-Sombke S, Frank MB, Dozmorov I, Ocheltree E, Kulmala P, Centola M, Ochs HD, Wells AD, Cron RQ
Journal of immunology (Baltimore, Md. : 1950) 2009 Jul 15;183(2):907-15
Journal of immunology (Baltimore, Md. : 1950) 2009 Jul 15;183(2):907-15
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.
Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E, Roncarolo MG, Battaglia M
Diabetes 2008 Sep;57(9):2341-7
Diabetes 2008 Sep;57(9):2341-7
Defense of the clone: antibody 259D effectively labels human FOXP3 in a variety of applications.
Fox BC, Bignone PA, Brown PJ, Banham AH
Blood 2008 Apr 1;111(7):3897-9
Blood 2008 Apr 1;111(7):3897-9
Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.
Tran DQ, Ramsey H, Shevach EM
Blood 2007 Oct 15;110(8):2983-90
Blood 2007 Oct 15;110(8):2983-90
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM
Blood 2006 May 1;107(9):3639-46
Blood 2006 May 1;107(9):3639-46
Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V, Smythe K, Dai Z, Spies T
Nature immunology 2006 Jul;7(7):755-62
Nature immunology 2006 Jul;7(7):755-62
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY
Proceedings of the National Academy of Sciences of the United States of America 2006 Apr 25;103(17):6659-64
Proceedings of the National Academy of Sciences of the United States of America 2006 Apr 25;103(17):6659-64
No comments: Submit comment
Supportive validation
- Submitted by
- BioLegend (provider)
- Main image
- Experimental details
- Human PBMCs were surface stained with CD4-APC, CD25-PE and intracellular stained with 259D/C7 Alexa 488.
- Conjugate
- Green dye